CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
about
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyTurning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in CancerAntibody Drug Conjugates: Preclinical ConsiderationsSialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharidesTargeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationAKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinHigh efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.The influence of Cox-2 and bioactive lipids on hematological cancers.Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Finding minimum gene subsets with heuristic breadth-first search algorithm for robust tumor classification.Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid LeukemiaCorrelation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyIdarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).Recent advances in targeted therapy of human myelogenous leukaemia.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenograftsNewer developments in immunohistologyDecitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blastsTargeted therapy in leukemia.Basic and clinical immunology of SiglecsMonoclonal antibody-induced cytokine-release syndrome.Investigational antibody-drug conjugates for hematological malignancies.Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.Pharmacogenomic considerations of xenograft mouse models of acute leukemia.New therapeutic approaches to acute myeloid leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.Recent developments in immunotherapy of acute myeloid leukemia.Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemiaAntibody-Based Treatment of Acute Myeloid Leukemia.Novel agents for the treatment of childhood leukemia: an update.Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage.The optimal dosing of gemtuzumab ozagamicin: where to go from here?Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
P2860
Q24678297-48EE9B84-080E-4C39-B13F-A1F6B3B7E764Q26744538-F50C891F-1AE8-428E-8254-11C482C7A6E7Q27022321-24E5AB6F-3C71-45F1-B945-32BA7577476AQ28247592-AA5E4408-0364-44E1-B149-982C63C68811Q28476825-5E6FEFE0-0F02-4237-A6D3-D89FC877FBCEQ28484890-5DC22B19-754F-43E1-8080-AD10048B506DQ33373033-B138F9E0-CDE8-4F27-AED9-1B783A3A6A72Q33688673-DFFC565D-04C1-41ED-B5EE-88BDEC7CF346Q33729158-B02BB046-AD12-44C0-B2DB-1F4ECD6F7479Q33840201-BBF6A9E0-D414-4310-99D7-ABBBF2F7D6EBQ34351520-630201FC-11CF-454C-9ECB-1E3283A4A884Q35146288-9B585A38-94CD-4C68-89AA-F0B14686BCB8Q35446333-E6F58D24-99FD-4DBD-B11C-469307DEDC5CQ35681332-F6227D9D-B236-4F84-85D5-F38A14EF3B6DQ35909648-C0D18AFC-0319-4D5B-837B-ED27FAB80056Q35930622-C708FC56-873C-4AD7-8E53-8DBAFD617391Q36058588-50576FF4-4B4C-45B9-9CC9-32D437AE6879Q36158816-9555960F-7697-47B7-860F-E561B6B5C85FQ36318531-64391B45-7BD5-4F0C-8712-D0E17F982C3FQ36367816-89F9D339-C2C2-48D7-A1B0-96603B0794D4Q36591404-9C726646-AC3E-4C9C-A10E-660083F5EEA8Q36637725-26402BB8-6D21-4D8A-9E89-250E2EC88437Q36989586-84A481F6-870B-4905-B1C4-C3F4BF5E9DD8Q37147758-577AB441-8DF8-49C0-A881-57A6017E3B5EQ37348437-0CA415F2-F2E6-4729-B4CC-4E86763CD470Q37755276-6DC6EA59-746F-4199-879E-A4893438A45FQ37818256-F3E426E1-020E-454A-A1F4-79DA8C94B69BQ37910260-D7C61F25-E66F-45E5-9AD0-658C34FEEFB0Q38061500-22C79A6D-642C-4D25-9D01-8BCF6CCF3532Q38090673-CD6649D1-FE12-46A5-A925-5916E0DD538EQ38109541-9878E913-A9DE-4549-BD1A-CA62C0543E7AQ38131563-355B1498-1B5C-4647-B626-6B24C355B70FQ38383345-82A44608-B92B-4A82-9DB7-3507EA8FBB26Q38661895-0FEFDB29-0117-4A37-A8F8-F49B5166A399Q38972314-7192A5F5-6D7D-42DD-9496-4E710BEC17B3Q38979277-A20F83B9-599F-4518-87DE-730880CBE96EQ39455649-2CA64BDE-0DBE-4A3F-8408-26158144CD04Q40337699-0C5B09A4-6850-4BD0-BDF8-6055F370D553Q42397467-0BE27855-02E3-4C10-8251-9682C60928D9Q43461402-4F69984B-7291-4090-8A65-19F78227B6F6
P2860
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
CD33-directed therapy with gem ...... mechanisms of drug resistance.
@ast
CD33-directed therapy with gem ...... mechanisms of drug resistance.
@en
type
label
CD33-directed therapy with gem ...... mechanisms of drug resistance.
@ast
CD33-directed therapy with gem ...... mechanisms of drug resistance.
@en
prefLabel
CD33-directed therapy with gem ...... mechanisms of drug resistance.
@ast
CD33-directed therapy with gem ...... mechanisms of drug resistance.
@en
P2860
P356
P1433
P1476
CD33-directed therapy with gem ...... mechanisms of drug resistance.
@en
P2093
M L Linenberger
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403598
P577
2005-02-01T00:00:00Z